Kura Oncology (KURA) Shares Outstanding (Weighted Average) (2010 - 2026)

Kura Oncology (KURA) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $88.6 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $88.6 million, up 1.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.6 million (up 1.37% YoY), and the FY2024 annual result was $86.2 million, up 17.66% from the prior year.
• Shares Outstanding (Weighted Average) grew to $88.6 million in Q1 2026 per KURA's latest filing, from $840585.0 in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $88.6 million in Q1 2026 and troughed at $840585.0 in Q2 2025.
• A 5-year average of $61.6 million and a median of $68.8 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) grew 25.37% in 2024, then sank 99.03% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $67.0 million in 2022, then grew by 9.31% to $73.2 million in 2023, then increased by 17.66% to $86.2 million in 2024, then tumbled by 99.02% to $840585.0 in 2025, then soared by 10441.47% to $88.6 million in 2026.
• Business Quant data shows KURA's Shares Outstanding (Weighted Average) at $88.6 million in Q1 2026, $840585.0 in Q3 2025, and $840585.0 in Q2 2025.